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Introduction
This project examines the relationship between PPARγ and carcinogenesis. PPARγ sits at a critical juncture in cellular differentiation and metabolism being involved in both differentiation and in the regulation of stress responses mediated through the cyclooxygenase (COX) and lipoxygenase (LOX) pathways of fatty acid metabolism. The basis for this project was the observation that in human prostate cancer there is an early loss of enzymes responsible for the production of the putative endogenous ligands for PPARγ, presumed to result in a decrease in receptor function. We have found that loss of PPARγ function can result in the generation of premalignant prostatic lesions in mice (Jiang et al 2009) .
We have also shown that there is an associated upregulation of COX pathways which would generate increases in prostaglandin production and oxidative stress, which could underlie such a pathology. This project sets out to examine interactions between the PPARγ, COX and LOX pathways and their role in carcinogenesis. We are using predominantly tissue recombination models involving human prostatic epithelial cells. The use of human cells is important in that there are significant differences between the fatty acid metabolic pathways between humans and mice.
Body
Status of progress in relation to the original SOW is summarized below:
Task 1. Examine the in vivo consequences of suppression of PPARγ signaling in human prostatic epithelium.
Generate and test PPRE-luciferase reporter construct (months 1-3) Completed.
Generate and test viral vectors carrying siRNA targeting human PPARγ1 and γ2 (months 1-4)
Completed.
Grow up and infect hPrE and hPrEshp16 cells using PPARγ siRNA and PPRE-luc viral particles. Select infected cells (months [4] [5] [6] [7] [8] . Completed siRNA phase -some modifications to specific cells used noted below.
Validate function of viral constructs in cells (Western blot and luciferase assay -qRT-PCR can also be used for the PPRE-luc is PPARγ1 suppression is unexpectedly efficient) (months 5-9) Completed.
Generate and graft tissue recombinants using infected epithelial cells and NPF and CAF (or rUGM controls) (months 6-10) Completed.
Harvest recombinants, process for biochemical and immunohistochemical analysis (months [10] [11] [12] [13] [14] [15] [16] [17] Completed.
Histopathologic assessment of slides (months [15] [16] [17] [18] [19] [20] . Completed.
Generation and analysis of proliferative and apoptotic indices (months [15] [16] [17] [18] [19] [20] Ongoing.
Summation of data set and manuscript preparation (months 20-24) Ongoing.
Task 2. Examine the in vitro and in vivo consequences of overexpression of cyclooxygenase -1 or -2 or

15-lipoxygenase-1 in human prostatic epithelium.
Generate and test viral vectors carrying expression constructs for COX-1, COX-2 and 15-LOX-1 (months 2-5). Completed.
Grow up and infect hPrE and hPrEshp16 cells using PPRE-luc viral particles in combination with COX-1, -2 or 15-LOX-1 overexpression viral vectors. Select infected cells (months 5-9). Completed.
Validate function of viral constructs in cells (Western blot and luciferase assay) (months 5-10)
Completed in modified form, as noted below.
Generate and graft tissue recombinants using infected epithelial cells and NPF rUGM (months 6-10)
Ongoing.
Harvest recombinants, process for biochemical and immunohistochemical analysis (months [10] [11] [12] [13] [14] [15] [16] [17] Ongoing.
Histopathologic assessment of slides (months [15] [16] [17] [18] [19] [20] Ongoing.
Generation and analysis of proliferative and apoptotic indices (months 15-20) Ongoing.
Summation of data set and manuscript preparation (months [20] [21] [22] [23] [24] ) Not yet started.
Task 3. Examine protective effects of PPARγ agonists and/or COX/LOX inhibitors against the neogenesis of PIN or progression of prostate cancer.
Ongoing -see note below regarding tissue collection for this task.
Summary of Activity
We have been pursuing the project as outlined in the statement of work, as noted above. In general, the work is proceeding as planned and on time. The mouse work, which was the basis for this project, although not strictly a part of it, is completed and will be published in October 2009 (advanced electronic publication appended). Confirmation that the same premalignant changes and progression seen in murine cells also occur in human epithelial cells has been generated using siRNA knockdown of PPARγ-1/-2 in human prostatic epithelial cell lines NHPrE1 and BHPrE1, NHPrE1-C-MYC-and NHPrE0-SV40Tag/hTERT followed by tissue recombination with prostate-inductive rat urogenital sinus mesenchyme (rUGM).
As described in the first annual report we have generated new human prostatic epithelial cell lines which better recapitulate human prostatic biology than those that were available at the time of submission. A descriptive manuscript is currently in revision in Stem Cells. Consistent with the first task in the statement of work we have shown that PPARγ suppression in these cells results in the formation of a low grade PIN phenotype.
In order to further develop this model we have combined PPARγ suppression with other genetic insults.
Specifically we have used combinations of PPARγ suppression along with c-Myc activation or SV40T expression. The findings of these studies, which are currently being written up for publication, are that addition of c-myc to PPARγ suppression gives rise to a high grand PIN phenotype with some foci of invasion, while the use of PPARγ suppression in a human prostatic epithelial cell line immortalized with SV40T gives rise to high grade PIN and local invasive cancer. Due to the relatively uncontrolled nature of SV40T action we are limiting pursuit of this model, but will pursue the PPARγ/myc combination. As noted in the first annual report we initially proposed to use epithelial cells in which p16 was knocked down as a second genetic insult and we have been exploring these other options as an alternative.
In the first annual report we described the possible use of PTEN and PPARγ co-suppression, using a tetracycline regulated PTEN suppression construct. However unexpected cross talk between tetracycline activity and the PPARγ pathway has made data generated in this way challenging to interpret. While these results are interesting they are probably not pertinent to the main thrust of this proposal and as such are no longer being actively pursued.
In task 2 we have continued studies in which the expression of lipoxygenase and cyclooxygenase is regulated (expression or suppression). We have now generated COX-1 and -2, 15-LOX-1 overexpressing cells which have all been validated and recombinants have been generated as proposed. These experiments are currently in mice awaiting harvest. 15-LOX-2 suppression experiments are slightly more advanced but the data have not yet been analyzed.
As described in the first annual report the movement toward laparoscopic/robotic prostatectomy has had a negative impact on the quality of tissue available for research, required for task 3. We have worked with the VICC Tissue Acquisition Core to sidestep this problem and with some of the urologic surgeons to modify their technique -allowing the tissue to be removed from the body cavity immediately after resection, rather than at the end of the procedure. This limits the time that the tissue is kept warm but with no blood supply. This modification, while it is slowing down tissue collection does seem to be improving recovery of tumor. PPARg regulates differentiation, proliferation and apoptosis in both stromal 4 and parenchymal epithelial cells, [5] [6] [7] [8] involving in many signaling pathways during the pathogenesis of inflammation and oxidative stress. 9, 10 The links between PPARg target genes and the relevance of alterations of PPARg functions to human pathology are beginning to be elucidated.
Key Research Accomplishments
11
Many prostate cancer (Pca) patients with early disease could potentially be treated conservatively. Tissue-based and in vitro studies suggest that alterations in PPARg activity may be involved in Pca and that PPARg may be a candidate target for Pca therapy. [12] [13] [14] Recent studies have reported autophagy in prostate cancer cell lines. [15] [16] [17] To gain insights into whether autophagy is involved in the processes of dysregulated lipid metabolism and induced oxidative stress accompanying the prostate proliferative epithelial lesions, we characterized the PPARgdeficient mouse prostate models. Autophagy accompanied the altered cellular proliferation and differentiation that resulted from PPARg-deficiency in mouse prostate models. This paper examines the links between PPARg activity and the subcellular and histopathologic changes taking place in the murine prostate. Details of these changes were examined using parallel in vitro models.
Results
Progressive mPIN in PBCre4
tg/0 /PPARc flox/flox transgenic mice. We generated PBCre4 tg/0 /PPARg flox/flox double transgenic mice on a C57/Bl6 background. A PBCre4 tg/0 / PPARg flox/flox mouse line was selected which strongly excised exon 2 of PPARg (both g1 and g2 isoforms) in the anterior (AP) and ventral prostate (VP) with weaker excision in the lateral (LP) and dorsal (DP) prostatic lobes. Loss of prostatic PPARg protein expression was confirmed using immunohistochemistry (Supplementary Information S1a).
The prostatic phenotypes of mice carrying two flox alleles but no Cre were indistinguishable from their WT counterparts. Beginning at three months of age we observed histologic alterations indicative of mPIN in the KO mice. 18, 19 Epithelial hyperplasia with mild cytologic atypia and local inflammatory cell accumulation was observed in the AP and VP (Figure 1a ), but not in the DP and LP. The involved lobes showed epithelial stratification, consistent with increased cell proliferation. Nuclei were enlarged, with mild hyperchromasia and focally more prominent nucleoli, compatible with lesions previously categorized as mouse prostatic intraepithelial neoplasia (PIN) I in genetically engineered mouse (GEM) models 19 here designated low grade PIN (LGPIN).
Older KO mice showed progressively more widespread prostatic epithelial hyperplasia with increased nuclear atypia in AP and VP, satisfying key criteria for NCI MMHCC mPIN. 18 These progressive changes were similar to lesions designated as PIN II and III 19 (Figures 1b-c) here designated high grade PIN (HGPIN). Cytoplasm was increasingly amphophilic, suggesting decreased secretory differentiation. Nuclear enlargement with chromatin clumping and prominent nucleoli was noted ( Figure 1 ). No foci of invasive carcinoma were identified in PPARg KO mice up to 15 months of age.
No significant gross differences were seen between prostatic lobe weights from 12 month old KO and WT mice (Supplementary Information S1b). In the AP, decreased branching and associated expansion of some individual AP ducts were noted in KO versus control mice, first discernible in the 7-12 month age group (Figure 1d ).
PAS staining illustrated decreased luminal secretions in the conditional PPARg KO mouse prostatic epithelia (Supplementary Information S1c). AR (Supplementary Information S1c) and cytokeratin 18 (CK-18) (data not shown) were expressed throughout the luminal epithelium of the normal prostate and decreased in the PIN epithelium.
The stroma was thickened around mPIN lesions with strong co-expression of a-smooth muscle (SM)-actin (Supplementary Information S1c) and vimentin (data not shown) consistent with a reactive myofibroblastic phenotype. An inflammatory response composed of mononuclear cells consistent with macrophages and lymphocytes was observed in 25% of the PPARg KO prostates, whereas it is not commonly noted in WT mouse prostates. 18 Histologically, limited hyperplasia was found in the AP and DP of WT mice from 3 months. More widespread hyperplasia was seen in the AP and VP of PPARg KO mice from early stages. mPIN was observed in the AP and VP of PPARg KO mice (Figures 1e-h ). The scores given in Figures 1e-h represent incidence of disease. When extent of disease was examined it was noted that the individual foci were markedly larger in older versus younger mice. Samples were scored by the presence of the most severe phenotype irrespective of its prevalence. mPIN was not seen in WT mouse prostates. In marked contrast, a 36.4% incidence of PIN (27.3% LGPIN plus 9.1% HGPIN) was observed in the AP of PPARg KO prostate in p6 months, 26.9% PIN (7.7% plus 19.2%) in 7-12 month animals and 25% PIN (10% plus 15%) in X13 months old mice. 100% PIN (54.5% plus 45.5%) was found in the VP of PPARg KO prostates in p6 months, 84.6% PIN (38.5% plus 46.1%) in 7-12 months and 60% PIN in (40% plus 20%) in X13 months. Histopathologic characterization indicates that PPARg is a regulator of mouse prostate epithelial cell differentiation and that its loss results in generally progressive mPIN.
Establishment of PPARc-and PPARc2-deficient mouse prostate epithelial cell lines. Two PPARg-and PPARg2-deficient cell lines were developed. A spontaneously immortalized line was generated from the prostatic epithelium of a KO mouse. These mPrE-PPARg KO (mPrE-gKO) cells incorporate complete functional deletion of PPARg, confirmed by PCR analysis (Figure 2a) . A human U6-driven mouse PPARg2 shRNA retroviral construct was introduced into a WT mouse prostatic epithelial cell line (mPrE). 20 These cells are designated mPrE-PPARg2 shRNA (mPrE-g2sh). Western blot analysis demonstrated that the mPrE-gKO cells have no PPARg1 and g2 protein expression while the PPARg2 shRNA construct was effective at reducing PPARg2 protein expression (Figure 2b ). The pSIR empty vector was used to make control cells (mPrE-pSIR).
mPrE-gKO and mPrE-g2sh cells appeared similar, the cells were small and elongated with enlarged nuclei (Figures 2c  and e) . The PPARg-and PPARg2-deficient cells grew as discreet individual cells with reduced cell-cell contact and with increased viability and proliferation (Figures 2d and f) . Cell cycle analysis also showed fewer cells in S phase with mild increase in G0/G1 arrest and essentially no change in G2/M (Supplementary Table 1 ). mPrE-gKO and mPrE-g2sh cells formed notably larger clones in a clonogenicity assay, than either mPrE or mPrE-pSIR cells (Figure 2g ). Suppression of PPARg activity was confirmed using a luciferase reporter driven by a triple AOX-PPRE 21 ( Figure 2h ). PPARg protein was undetectable by immunofluorescence (IF) staining in the nuclei of mPrE-gKO and mPrE-g2sh cells (Figure 3a ). p63 and CK-14 proteins were used to identify basal epithelial cells. 18 But, p63 was weak to absent and cytokeratin (CK-14) protein expression was weaker in PPARg-/g2-deficient cells in vitro (Figure 3a and Supplementary Information S2a). b-catenin protein expression was lost in the cellular membrane of growing colonies but was detected in the nuclei (Figure 3a) . Western blot analysis demonstrated that p63, CK-14, b-catenin and E-cadherin proteins decreased in mPrE-gKO PPARc-and PPARc2-suppression in a prostatic tissue recombination model resulted in mPIN pathogenesis.
To determine the consequences of PPARg-and PPARg2-suppression in mouse epithelial cells in vivo with physiologically relevant epithelial-stromal interactions, we used a tissue recombination model. Recombinants composed of untransfected mPrE cells or control mPrEpSIR recombined with rat UGM formed glandular structures lined with cuboidal to columnar secretory epithelium surrounded by stroma resembling normal rodent prostate, consistent with previous observations 20 (Figures 3c-f ). Tissue recombinants using either mPrE-gKO or mPrE-g2sh cells exhibited similar mPIN phenotypes within two months of grafting (Figures 3c-f ). Mild degrees of epithelial stratification, mild nuclear alterations, and reduced secretory The cellular morphology and proliferation of mPrE-g2sh and mPrE-pSIR cells in culture. Phenotypically these cells showed changes similar to those evoked by the knockout of PPARg in the mPrE-gKO cells. Suppression of PPARg2 protein expression resulted in increased cellular proliferation. (g) mPrE-gKO and mPrE-g2sh cells form larger clones compared to control mPrE and mPrE-pSIR cells when tested using a clonogenicity assay. (h) PPRE activity detected by a luciferase reporter showed a 485% decrease in the mPrE-g2sh cells as compared to mPrE controls. Signal was undetectable in mPrE-gKO cells. Rosiglitazone has no effect on PPRE activity of mPrE-gKO cells. However it shows mild activation on PPRE activity of mPrE-g2sh cells, confirming that these cells retain a weakened ability to respond to this PPARg agonist Western blot analysis demonstrated that p63, CK-14, b-catenin and E-cadherin proteins decreased in mPrEgKO and mPrE-g2sh cells compared to mPrE and mPrE-pSIR controls. LNCaP and PC-3 cells were used as the controls. (c and e) Histology of tissue recombinants using rat urogenital sinus mesenchyme (UGM) with mPrE, mPrE-gKO, mPrE-pSIR and mPrE-g2Sh cells examined at two months post-grafting. The control recombinants resembled prostatic glandular differentiation although with some flattening of epithelial layers consistent with previous descriptions. Tissue recombinants made using mPrE-gKO (c) and mPrE-g2sh (e) cells grew less readily. Histopathologically these structures exhibited a phenotype consistent with mPIN with epithelial crowding and tufting and out-growths (arrow). Scale bar ¼ 50 mm. (d and f) Gross appearance of tissue recombinants using mPrE and mPrE-pSIR cells were similar, showing glandular differentiation by two months post grafting. In contrast tissue recombinants made using mPrE-gKO (d) cells and mPrE-g2sh (f) cells grew less readily and exhibited a less obviously glandular phenotype
Cell Death and Differentiation
Autophagocytosis in PPARc knockout and PPARc2 knockdown mouse prostate epithelial cells. Ultrastructural analysis was performed on AP tissues from 12-month-old conditional PPARg KO and WT mice. WT AP is illustrated (Figure 4a ). Foci of mPIN PPARg KO mouse were examined by electron microscopy. The secretory luminal cells of WT prostate were cylindrical with supra-nuclear vesicles including some budding from the rough endoplasmic reticulum (RER) (Figures 4b-c) . Number, size and distribution of mitochondria, lysosomes and peroxisomes were unremarkable. Secretory vesicles were found budding from the Golgi, and mature and exocytosing secretory vesicles were also observed. In contrast, the PPARg KO luminal epithelial cells in mPIN regions had a number of Figure 4 Increased autophagic features in the ultrastructure of PPARg knockout prostate epithelium and mPrE-PPARg2 shRNA cells. Light and electron microscopy of prostate tissue indicated significant morphological differences between WT (a-c) and PPARg KO (d-f) mice at the age of 12 months. Toluidine blue staining of thick plastic sections (a and d) indicated increased cellularity and fewer secretory vesicles in the epithelium from PPARg KO mice prostate. Scale bar (a and d) ¼ 50 mm. Ultrastructurally, the WT mouse prostate epithelial cells showed a normal distribution of cytoplasmic constituents, organelles and secretory vesicles (b and c). In contrast, the PPARg KO cells had abnormal appearing mitochondria and increased numbers of lysosomes. The lysosomes had varied morphology. Some exhibited a classical appearance (e and f) or appeared as multivesicular bodies (f) while others had the appearance of autophagosomes (g-j). Scale bars: (b) ¼ 2 mm, (c) ¼ 500 nm, (e) ¼ 2 mm, (f) ¼ 500 nm, (g) ¼ 500 nm, (h) ¼ 100 nm, (i) ¼ 100 nm and (j) ¼ 500 nm. Cytoplasmic organelles in mPrE and mPrE-pSIR cells had a normal distribution and ultrastructural appearance (k and m). In contrast mPrE-gKO cell demonstrated a decrease in mitochondria and increase in secondary lysosomes (l). Inset: increase magnification image lysosome containing numerous membranes and other debris, suggestive of autophagosome. mPrE-g2sh cells had increased lysosomes, many having the appearance of autophagosomes (n). Inset: autophagosome. Scale bars (k) ¼ 500 nm, (l) ¼ 1 mm, (m) ¼ 2 mm and (n) ¼ 500 nm (Figures 4e-f) . The lysosomes varied in size and many showed features suggestive of autophagocytosis, including both early and late autophagosomes. 22 The PPARg KO epithelial cells in mPIN foci contained clusters of variably sized autophagic vacuoles (autophagosomes) containing loose granular to more dense flocculent substance. Features suggesting autophagocytosis included double membranes, internal vesicles, and the presence of organelles such as mitochondria, peroxisomes, and rough endoplasmic reticulum within the lysosome (Figures 4f-j) . There were also a number of multivesicular bodies (Figure 4f ). Fewer normal-appearing secretory vesicles were present (Figures  4e-f) . In some places, the basement membrane was disrupted at the site of basal cell attachment (Figure 4e ). These changes were consistent with a reduction in secretory differentiation of prostatic luminal cells and possible increase in autophagy in the proliferating mPIN regions.
mPrE-pSIR and mPrE cells exhibited normal number, size and distribution of cellular organelles and secretory vesicles (Figures 4k and m) . In contrast, the mPrE-gKO and mPrEg2sh cells had a substantially increased range of lysosomal sizes where the majority were small and distributed as clusters within the cytoplasm. Many of these were complex with lipid whorls and internalized material, including mitochondria, peroxisomes and rough endoplasmic reticulum, in various stages of digestion (Figures 4l and n) . Thus, while the changes were more dramatic in the mPrE-g2sh cells, the overall ultrastructural alterations were reminiscent of the cytoplasmic changes noted in the prostatic epithelium from PPARgKO mice and were consistent with increased autophagocytosis (autophagy).
Gene expression profiles in the mPrE-gKO cells vs. mPrE cells or mPrE-g2sh cells vs. mPrE-pSIR cells demonstrated major changes (Table 1) including alterations in signaling pathways involving genes of the nuclear receptor II subfamily, cell cycle control (dedifferentiation), peroxisomal and mitochondrial lipid transporter and oxidation metabolism (oxidative stress/hypoxia) and ubiquitination/proteosomal degradation. Ingenuity Pathway Analysis (IPA, Ingenuity Systems) was used to evaluate changes based on microarray data. The top canonic pathway and network related to PPARgsignaling signatures were metabolism pathway/oxidative stress (Supplementary Information S3a-b) and cell cycle control/dedifferentiation (Supplementary Information S4a-b). Effects were generally consistent between PPARg KO and PPARg2 shRNA prostate epithelial cells as compared to control cells.
Altered expression patterns of autophagy-associated proteins were detected in mPrE-gKO and mPrE-g2sh cells compared to the control cells (Figure 5a ). LC-3 (Atg8), beclin-1 (Atg6), activated caspase-3, PCNA (Figure 5a ), and COX-2 and vimentin (Supplementary Information S2a) were increased, whereas catalase ( Figure 5a ) and PMP70 (data not shown) were decreased in two PPARg-/g2-deficient cell lines.
Monodansylcadaverine (MDC), a marker of autophagy, 22 was visualized in the mPrE and mPrE-gKO, mPrE-pSIR and mPrE-g2sh cells under 5% FBS (regular growth) or 2.5% FBS (semi-starvation) culture conditions. Elevated MDC signaling was seen in both mPrE-gKO and mPrE-g2sh as compared to control cells. This was enhanced in 2.5% FBS culture medium (Figure 5b ). Lysosomes and mitochondria were tracked, using LysoTracker (DND-99) and MitoTracker, 22 respectively, under the 5% or 2.5% FBS culture conditions. The LysoTracker (Supplementary Information S2b) and MitoTracker (data not shown) signaling were strongly increased in PPARg-/g2-deficient cell lines in 2.5% FBS culture medium.
In vivo, catalase ( Figure 5c ) and PMP70 (data not shown) proteins were found to be decreased or lost in mPIN foci of KO mice. In contrast, LC-3 protein (Figure 5c ) was increased in the mPIN foci of KO mice compared to the epithelium of WT mice.
Active PPARc1/c2 signaling suppresses the phenotypes in mPrE-PPARc KO cells and mPrE-PPARc2 knockdown tissue recombinants. To dissect the biological functions of PPARg1 and PPARg2 isoforms we re-expressed PPARg1 or PPARg2 cDNA into mPrE-gKO cells viral transduction of wildtype full-length cDNA. 23 Three cell lines, mPrE-PPARg KOempty vector (mPrE-gKO-EV), mPrE-PPARg KO-PPARg1 WT (mPrE-gKO-g1WT) and mPrE-PPARg KO-PPARg2 WT (mPrE-gKO-g2WT), were established (Figure 6a ). Western blotting confirmed re-expression of the PPARg1 or PPARg2 isoform (Figure 6b) . IF staining showed positive nuclear PPARg protein in mPrE-gKO-g1WT and mPrE-gKO-g2WT cells compared to the control mPrE-gKO-EV cells (Figure 6a ). While total b-catenin levels were not greatly altered there was a marked shift in localization from the nuclei in the KO cells to the cytoplasm and membrane in the PPARg1-/g2-expressing cells (Figure 6a ). Elevated levels of E-cadherin (Figure 6b ), but not CK-14 and p63 proteins (data not shown), were seen in mPrE-gKO-g1WT and mPrE-gKOg2WT cells. EM showed decreased lysosome and autophagosome volume and increased numbers of mitochondria in the PPARg1-/g2-rescued mPrE-gKO cells compared to the control mPrE-gKO-EV cells (Figure 6c) . mPrE-gKO-g1WT and mPrE-gKO-g2WT cells showed decreased cell viability and proliferation (Supplementary Information S5a) as well as clonal formation (Supplementary Information S5b). As expected mPrE-gKOg1WT and mPrE-gKO-g2WT cells showed increased PPREactivity by a luciferase reporter assay (Supplementary Information S5c). IF staining showed increased levels of CK-14 and catalase (Supplementary Information S5d) , decreased levels of caspase-3 activation (Figure 6a ), LC-3 and PCNA (Supplementary Information S5c) , and beclin-1 (data not show) in the PPARg1-/g2-rescued cells compared to the mPrE-gKO-EV control cells.
Tissue recombinants of mPrE-g2sh cells showed decreased secretion and immunophenotypic features of PIN phenotypes cnsistent with PPARg KO mouse prostates. These included reduction in p63 positive basal cells and AR (Figure 6d ) with lesion progression and phenotypic alterations in stromal cells visualized by a-SM-actin staining (Figure 6d ).
Basal cells progressively decreased as the mPIN lesion
Disruption of PPARc results in autophagy and mPIN M Jiang et al 7 progressed, similar to the pattern recognized in human PIN progression and in progressively severe mPIN in some GEM models. 18 To examine the potential for targeted chemoprevention with pharmacologic PPARg agonists, tissue recombinants composed of mPrE-g2sh cells plus rat UGM were grown for three months in animals which were continuously fed on chow containing the PPARg agonist Rosiglitazone. At sacrifice the grafts in these animals were of similar size to mPrE-pSIR controls and on histologic examination, secretory differentiation of luminal epithelial cells and intraluminal secretions were increased compared to mPrE-g2sh recombinants without drug treatment. mPIN-like changes were reduced compared to grafts of control mice fed on standard animal chow. Rosiglitazone treatment enhanced p63 and AR expression and also modified the stromal compartment in mPrE-g2sh tissue recombinants (Figure 6d ).
These data support the roles of reduced PPARg function in the development of mPIN and indicate that re-expression of either PPARg1 or PPARg2 isoform in PPARg KO cells is able to rescue the phenotype. Rosiglitazone treatment suppressed mPIN formation in mPrE-g2sh tissue recombinants, likely by activating transcription through PPARg1, although PPARgindependent effects cannot be excluded.
Discussion
Elucidating the molecular pathologic mechanisms underlying prostatic carcinogenesis may allow for more conservative targeted medical treatments for certain low risk patients with precursor lesions or organ confined, small volume, low grade carcinomas. The ability to medically inhibit progression of HGPIN to Pca or the progression of small, lower grade Pcas Global gene expression profiling in mPrE-PPARg knockout cells vs mPrE cells or mPrE-PPARg2 knockdown cells vs mPrE-pSIR cells. The major signaling pathway changes in mPrE-gKO cells vs mPrE cells and mPrE-g2sh cells vs mPrE-pSIR cells by microarray analysis were involved in metabolic lipid oxidation, subcellular organelles/autophagy, oxidative stress, cell cycle regulation/cellular dedifferentiation and nuclear receptors/PPRE. Expression value of an individual gene was by the comparison of mPrE-gKO cells vs mPrE cells or mPrE-g2sh cells vs mPrE-pSIR control cells.
Disruption of PPARc results in autophagy and mPIN M Jiang et al
to larger, higher grade tumors would represent a significant advance for Pca patient management. We propose that PPARg is a key regulator in the maintenance of peroxisomal, mitochondrial and lysosomal functions. Genetic disruption of PPARg or PPARg2 signaling in mouse prostate epithelial cells resulted in dysregulated expression patterns of peroxisomal and mitochondrial genes whose products are involved in lipid transportation and oxidation pathways. Active autophagosomes and abnormally increased numbers of lysosomes were found in PPARg-and PPARg2-deficient prostatic epithelia. In vitro these phenotypes were rescued by re-expression of PPARg1 and PPARg2 isoform in mPrE-PPARg KO cells. In vivo changes consequent to loss of PPARg were associated with hyperplasia, PIN Figure 5 Alterations in autophagy-associated protein expression in mPrE-PPARg knockout and mPrE-PPARg2 shRNA cells. (a) Catalase, LC-3 (Atg8), beclin-1 (Atg6), caspase-3 and PCNA proteins were detected by immunofluorescence staining in mPrE and mPrE-gKO, mPrE-pSIR and mPrE-g2sh cells grown on glass slides for three days. Decreased catalase and increased LC-3 and beclin-1 were seen in mPrE-gKO and mPrE-g2sh cells compared to mPrE and mPrE-pSIR cells. These results suggested active autophagic body formation in the cells. Meanwhile, caspase-3 and PCNA were increased in PPARg-/g2-deficient cells. Scale bar ¼ 50 mm in the panels. (b) MDC, a marker of autophagy, was visualized in mPrE and mPrE-gKO, mPrE-pSIR and mPrE-g2sh cells under the 5% FBS regular or 2.5% FBS half-starvation culture conditions. Elevated staining was seen in both mPrE-gKO and mPrE-g2sh cells as compared to mPrE and mPrE-pSIR cells. The signals were strongly increased in PPARg-/g2-deficient cells in the 2.5% FBS culture media. Scale bar ¼ 50 mm in the panels. (c) Immunofluorescence staining of catalase and LC-3 in wild-type (WT) and PPARg knockout (KO) prostate tissue at ages of 7 months. Low levels of catalase expression and high expression of LC-3 protein were seen in the PIN regions (arrows) of PPARg KO mouse prostate epithelium compared to WT and more normal-appearing areas (arrowhead). Scale bar ¼ 50 mm in the panels formation and progression to malignancy, which in the case of PPARg2 suppression could be rescued using high levels of the PPARg agonist Rosiglitazone. The pathophysiological roles of PPARg in cellular peroxisomal and mitochondrial fatty acid oxidation and autophagy based on results are summarized in Figure 7 .
Alterations in lipid metabolism resulting in loss of PPARgsignaling have been suggested to predispose the prostate to premalignant or malignant changes. [24] [25] [26] The current study demonstrates, for the first time, that PPARg loss-of-function in wild-type mouse prostatic epithelium results in progressive epithelial hyperplasia with atypia, indicative of mPIN. Using Figure 6 Rescue of phenotypes of mouse PPARg-deficient prostate epithelial cells by re-expression of either PPARg1 or PPARg2 isoform or treatment by Rosiglitazone. (a) Phase-contrast microscopy morphology of control mPrE-gKO-empty vector and mPrE-gKO-PPARg1 or -PPARg2 WT cDNA cells, showing a return to a cobblestone morphology following reintroduction of each PPARg isoform. IF staining confirmed expression of PPARg protein in the nuclei of mPrE-gKO-g1WT and mPrE-gKO-g2WT cells (inset boxes). b-catenin protein was predominantly nuclear in mPrE-gKO whereas in mPrE-gKO-g1WT and mPrE-gKO-g2WT cells the protein was found in the cytoplasm and on intercellular membrane interfaces. Caspase-3 was decreased in mPrE-gKO-g1WT and mPrE-gKO-g2WT cells compared to mPrE-gKO-EV cells. Scale bar ¼ 50 mm. (b) Western blot analysis demonstrated PPARg1 protein in mPrE-gKO-g1WT and PPARg2 in mPrE-gKO-g2WT cells. b-catenin and E-cadherin protein levels increased in mPrE-gKO-g1WT and mPrE-gKO-g2WT cells compared to mPrE-gKO-EV control cells. (c) mPrE-gKO-EV cells had decreased mitochondria and increased lipid droplets and secondary lysosomes, similar to mPrE-gKO cells. Scale bar ¼ 2 mm. However introduction of the mouse PPARg1 wild-type cDNA increased mitochondria above wild-type values and decreased the presence of secondary lysosomes and lipid accumulation. Scale bar ¼ 250 nm. Likewise, introduction of the mouse PPARg2 wild-type cDNA into mPrE-gKO cells restored the level of mitochondria and reduced the instances of secondary lysosomes and lipid droplets. Scale bar ¼ 500 nm. (d) Tissue recombinants made using control (mPrE-pSIR) or mPrE-g2sh cells with rat UGM. Sections were examined for secretion by PAS. In control recombinants a normal prostatic phenotype with secretion was noted. In contrast in the mPrE-g2sh containing recombinants a low grade mPIN (arrow) with less secretion into the luminal space and thickened stromal was seen. p63 and AR protein were decreased in the mPrE-g2sh containing recombinants, but a-SM-actin protein expression was increased compared to tissue recombinants of mPrE-pSIR. Mice carrying tissue recombinants made by mPrE-pSIR and mPrE-g2sh cells were administered Rosiglitazone chow (0.005% Rosiglitazone) from the time of grafting until sacrifice at three months. Tissue recombinants of mPrE-g2sh in these mice (designated mPrE-g2sh þ Rosi.) showed secretion, and increased p63 protein in the basal layer and p63 negative-luminal differentiation by IHC staining (arrows). These recombinants showed well-differentiated prostatic glandular structure and a more normalappearing stroma. Scale bar ¼ 50 mm in the panels Disruption of PPARc results in autophagy and mPIN M Jiang et al both intact mice with targeted knockout of PPARg in prostate epithelium and a tissue recombination model with selective gene modulation in the epithelial compartment reduced PPARg function was associated with increased activation of oxidative stress, autophagic activity, and activation of proinflammatory signaling pathways. This establishes conditions for subsequent malignant transformation which would be expected to occur stochastically, resulting from epithelial genomic damage potentially caused by reactive oxygen species (ROS). 26 The results described here parallel reported changes in gene expression resulting in reduced ligands for PPARg in the human prostate and provide the first direct evidence that loss of PPARg expression or function can lead to prostatic neoplasia in vivo.
Reduced activation of PPARg due to reduced formation of endogenous ligands for PPARg most likely explains its role early in human Pca development. 8, 27, 28 Our studies demonstrate that PPARg plays a role in maintaining peroxisomal, mitochondrial and lysosomal biogenesis and maturation during prostatic epithelial cellular growth and differentiation. Catalase and PMP70 proteins were decreased in PPARg-and PPARg2-deficient prostate epithelial cells. Degenerated mitochondria were found in two PPARg-and -g2-deficient prostate epithelial cell lines. Active autophagosomes and abnormally increased numbers of lysosomes were found in PPARg-and PPARg2-deficient prostatic epithelia. These changes were associated with mouse PIN formation and progression. Microarray analysis revealed alterations to peroxisomal and mitochondrial fatty acid transporter synthesis and oxidative metabolism in both PPARg-and -g2-deficient mPrE cells as compared to the control cells. Disruption of PPARg-signaling results in altered fatty acid metabolism and induction of oxidative stress and hypoxia, as supported by the increased Hypoxia up-regulated 1 (Hyou-1) and Hairless (Hr), and decreased Hairy and enhancer of split1 (Hes1) gene expression in addition COX-2, GSTs and uPAR which show similar changes in expression patterns in clinical samples of human PIN and in other mouse models. 29, 30 A number of these altered genes contain a PPRE domain 31, 32 suggesting that these might be directly regulated. However, regulation of crucial genes could also occur indirectly, as a secondary consequence of reduced PPARg-signaling. The combination of light microscopic, ultrastructural, immunophenotypic, and gene expression data are consistent with dramatic changes in multiple subcellular organelles including mitochondria, peroxisomes and lysosomes, which likely contribute to the observed neoplastic phenotypes.
Our data suggest that the oxidative stress induced by PPARg loss-of-function results in lysosomal autophagy which can contribute to malignant progression. 33 Staining using lysosome tracker Red DNT-99 and autophagy markers MDC, LC-3 and beclin-1 showed increased signal strength in PPARg-and -g2-deficient mPrE cells in vitro and in vivo confirming autophagosome formation induced by active lysosomes, consistent with electron microscopy showing lysosomal changes. Changes included increased lysosomal number with variable sized including many small structures, often accumulating in clusters in PPARg-deficient mPrE cells. This appears to be an abnormal autophagic response which does not result in cell death, possibly allowing individual cells to avoid an increase in apoptotic activity (indicated by increased caspase-3 activation) induced by loss of PPARg activity.
The role of autophagy in cancer is complex. 34 Autophagy may be pro-tumorigenic, promoting tumor cell survival and restricting necrosis. 35, 36 Alternatively autophagy could represent either a barrier, or an adaptive response, to cancer. Here, using both deletion (PPARg KO) and suppression (PPARg2 shRNA) of PPARg in mouse prostate epithelial cells, we show increased autophagic activity. We suggest that PIN may indirectly result from the deregulation of pro-inflammatory pathways following PPARg inactivation combined with extension of life span via increased autophagic capacity. This outcome may be related to disruption of peroxisomal lipid oxidation/metabolism signaling pathways.
Early prostate cancer has been linked to a loss of enzymes including 15-lipoxygenase-2 (15-LOX-2) which is involved in the generation of 15(S)-hydroxyeicosatetraenoic acid (15-HETE). 8, 27 Such a scenario justifies the consideration of PPARg agonists as chemopreventive agents to inhibit the genesis of early stage prostate cancer. Based upon the data presented here we would suggest that modulation of PPARg signaling by glitazone drugs be considered as an addition to anti-oxidant diets to inhibit progression of HGPIN to prostate cancer.
Materials and Methods
Animal experiments. Floxed PPARg 37 and PBCre4 38 transgenic mouse lines have been described previously. PBCre4 mice were backcrossed in C57/Bl6 for more than 10 generations. Double transgenic PBCre4 tg/0 /PPARg flox/flox mice were generated by breeding the PBCre4 and floxed PPARg transgenic lines and were maintained in a C57/Bl6 background. Wild-type littermates were used as the control groups. PCR primers for PPARg genotyping and for detecting DNA recombination and excision have been previously reported. 37 Adult male severe combined immunodeficient (SCID) mice [C.B.17/IcrHsd-scid] were purchased (Harlan, Indianapolis, IN). All work involving animals was performed under protocols reviewed and approved by the Vanderbilt IACUC. Figure 7 Disruption of PPARg resulted in mouse prostate carcinogenesis involving oxidative stress and autophagy. The simplified diagram brings together data from the studies and presents a model illustrating how the PPARg signaling contributes to prostate carcinogenesis from wild-type to mPIN formation and to set up conditions that would predispose cells to further malignant progression. These data suggested an important role for the PPARg gene in maintaining the maturation, differentiation and turnover of subcellular organelles (peroxisomes, mitochondria and lysosomes) during mouse prostatic organogenesis and development. In particular this model suggests that a mechanism by which loss of PPARg could lead to mouse PIN related to the disruption of cellular peroxisomal and mitochondrial lipid metabolism and oxidative stress (hypoxia) and active autophagy for the extended life span and cellular dedifferentiation Mouse prostate lobes and tissue recombinants were dissected and fixed in 10% phosphate-buffered formalin overnight, transferred to 50% ethanol, then embedded in paraffin. Samples were sectioned for 8 successive layers at 5 mm intervals and stained with hematoxylin and eosin (H&E). IF and IHC were performed as previously described. 27 The observation was under a fluorescence microscope (ZEISS, Axio imager M1) equipped with an appropriate filter system. Electron microscopy (EM). Prostate tissue and fresh cell pellets were fixed in 2.5% glutaraldehyde in cacodylate buffer (0.1M, pH 7.2) overnight at 4 1C and washed in the same buffer for 30 min followed by post-fixation for 2 h at 4 1C in 1% osmium tetroxide (OsO4) in cacodylate buffer. After fixation, the material was dehydrated through a graded series of alcohols and embedded in Spurr Resin. For light microscopic analysis, semi-thin sections (2 mm) were stained with toluidine blue. Ultrathin sections (70 nm) were cut and ultrastructural analysis was performed on a Phillips CM-12 Transmission Electron Microscope operated at 80 KeV. Images were acquired using an AMT digital camera system. For quantification of lysosome number per area of cell cytoplasm examined, four separate thin sections were analyzed. The number of cross sections through lysosomes was counted and the area of cell cytoplasm represented in the four thin sections was determined. Given that most lysosomes are roughly spherical in shape, a lysosome would not be sampled twice in this procedure. Although, the exact number of lysosomes per cell cannot be obtained using this procedure, differences in the relative occurrence of lysosomes between wild type and PPARg-deficient cells can be estimated with reasonable accuracy.
Tissue recombinants and sub-renal capsule xenografting. Single cell suspensions of rat UGM were prepared from E18.5 embryonic fetuses as previously described. 20 Viable cells were counted using a hemacytometer. To prepare tissue recombinants, rat UGM was mixed with genetically modified mouse prostate epithelial cells at a ratio of 250 000 to 400 000. The cell mixture was pelleted and resuspended in 50 ml of rat-tail collagen (pretitrated to pH 7.4). After polymerization, the collagen was overlaid with growth medium. After incubation at 37 1C overnight, the tissue recombinants were grafted under the renal capsule of intact CB17Icr/Hsd-SCID mouse. Hosts were sacrificed at 4 weeks, 8 weeks and 12 weeks post-grafting. The kidneys with the grafts were removed and imaged before processing for histology.
Administration of Rosiglitazone to mice. Host SCID mice were fed by prepared BRL-49653 (Avandia or Rosiglitazone) chow (0.005 % Rosiglitazone) RTD C056 (TestDiet, Richmond, IN) 39 for seven days before xenografting surgery. And then subsequently for three months until sacrifice. The control mice were fed matched regular rodent chow.
Statistical analysis. A Statistical Analysis System (version 9.1, SAS Institute, Cary, NC) was used. Pathological index of wild-type and PPARg knockout mice were divided into four groups of Normal, Hyperplasia, LGPIN and HGPIN. Percent of each index in each lobe, (AP, VP, LP or DP), at different ages; p6 months, 7-12 months and X13 months was analyzed by Fisher's Exact Test. Differences were considered statistically significant at Po0.05.
Accession number. All microarray data have been deposited at the GEO database, accession number GSE13867 and a link for review:
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token ¼ dbgfxmkkaieiuny&acc ¼ GSE13867
